Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea's Celltrion Cuts Deal With Jordan-based Hikma To Sell Its Biosimilars In The Middle East, Africa

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Days after finalizing a deal to sell biosimilar therapeutic antibodies in Israel, Korea's Celltrion has signed a similar agreement with Jordan-based Hikma Pharmaceuticals to market the products across 17 Middle East and Northwestern African countries

You may also be interested in...



Jordan's Hikma Sees Double-digit Sales Growth In First Half, Continues Aggressive M&A Expansion In Middle East

Hikma, one of the fastest growing multinational pharmaceutical companies, reported group revenue Aug. 26 up 11.3 percent year-on-year for the first half of 2010. Diversified among branded, generic and injectables, the Jordanian drug maker attributed the growth to strong generics sales in the U.S

Jordan's Hikma Sees Double-digit Sales Growth In First Half, Continues Aggressive M&A Expansion In Middle East

Hikma, one of the fastest growing multinational pharmaceutical companies, reported group revenue Aug. 26 up 11.3 percent year-on-year for the first half of 2010. Diversified among branded, generic and injectables, the Jordanian drug maker attributed the growth to strong generics sales in the U.S

Korea's Celltrion Banks On Increasing Profits Resulting From New Focus On Biosimilars

SEOUL - Biopharmaceutical firm Celltrion posted a record performance in the most recent quarter due to the company's shift in focus from contract manufacturing to producing biosimilars

Related Content

UsernamePublicRestriction

Register

LL1132999

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel